The role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: a systemic review and meta-analysis

医学 肝细胞癌 危险系数 内科学 优势比 置信区间 乙型肝炎 荟萃分析 胃肠病学 子群分析 慢性肝炎 肿瘤科 免疫学 病毒
作者
Qi-Hang Cao,Hui Liu,Lun-Jie Yan,Zi-Niu Ding,Long-Shan Yang,Xin-Chen Mao,Guo-Qiang Pan,Bao-Wen Tian,Chen-Long Han,Zhao-Ru Dong,Dong-Xu Wang,Yu-Chuan Yan,Tao Li
出处
期刊:Research Square - Research Square
标识
DOI:10.21203/rs.3.rs-3017876/v1
摘要

Abstract Background The purpose of the current study was to investigate the predictive value of hepatitis B core-related antigen (HBcrAg) on the occurrence and recurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Methods Based on PubMed, Embase, Scopus, and Web of Science, we conducted a systematic review and meta-analysis of original clinical literature. The primary outcomes were the occurrence and recurrence of HCC assessed by the hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI). Results A total of 18 publications with 9039 CHB patients were included in the preliminary analysis. The pooled results suggest that HBcrAg positivity (adjusted HR = 3.10, 95%CI: 2.07–4.64, P < 0.001, I 2 = 62.4%, P = 0.021; OR = 5.65, 95%CI: 3.44–5.82, P < 0.001, I 2 = 0.00%, P = 0.42) was an independent risk factor for the occurrence of HCC. Further subgroup analysis revealed that 4.0 logU/ml may be the optimal cut-off value for HBcrAg to predict the occurrence of HCC. Our meta-analysis also suggests that HBcrAg is a predictor of HCC recurrence during antiviral therapy (adjusted HR = 1.71, 95%CI: 1.26–2.32; I 2 = 78.6%, P = 0.031) and is closely related to recurrence-free survival (RFS) after curative treatment of HCC (P = 0.001). Conclusion For patients with CHB, serum HBcrAg level is closely associated with the occurrence of HCC, regardless of whether nucleoside/nucleotide analogues (NAs) are administered, may also serve as a novel prognostic biomarker of recurrence in HCC. Confirmation of these findings requires more research.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Avvei完成签到,获得积分10
刚刚
2秒前
乐乐应助Dr.Liujun采纳,获得10
2秒前
伟大的鲁路皇完成签到,获得积分10
2秒前
生动茹妖完成签到,获得积分10
2秒前
完美世界应助南瓜气气采纳,获得30
3秒前
3秒前
4秒前
jinyue完成签到,获得积分10
6秒前
hh发布了新的文献求助10
7秒前
9秒前
lc完成签到,获得积分10
11秒前
14秒前
李健的小迷弟应助anna采纳,获得10
15秒前
量子星尘发布了新的文献求助10
15秒前
17秒前
17秒前
嘀嘀咕咕发布了新的文献求助10
17秒前
大观天下完成签到,获得积分10
17秒前
科研通AI2S应助科研通管家采纳,获得10
18秒前
英姑应助科研通管家采纳,获得10
18秒前
科研通AI5应助科研通管家采纳,获得10
18秒前
18秒前
科研通AI2S应助科研通管家采纳,获得10
18秒前
共享精神应助科研通管家采纳,获得10
18秒前
科目三应助科研通管家采纳,获得10
18秒前
bkagyin应助科研通管家采纳,获得10
18秒前
SciGPT应助科研通管家采纳,获得10
18秒前
CodeCraft应助科研通管家采纳,获得10
18秒前
orixero应助科研通管家采纳,获得10
19秒前
脑洞疼应助科研通管家采纳,获得10
19秒前
19秒前
兴奋千兰发布了新的文献求助10
20秒前
有机发布了新的文献求助10
21秒前
yukang发布了新的文献求助10
21秒前
23秒前
大观天下发布了新的文献求助30
24秒前
24秒前
26秒前
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073